Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)

Schizophrenia Research

Volumn 134, Issue 2-3, 2012, Pages 187-194

  Grimaldi Bensouda, Lamiae ^a,k   Rouillon, Frederic ^b   Astruc, Bernard ^c   Rossignol, Michel ^d,n   Benichou, Jacques ^e,o   Falissard, Bruno ^c,f,p   Limosin, Frederic ^f,g,q   Beaufils, Beatrice ^g   Vaiva, Guillaume ^h,r   Verdoux, Helene ^e,i   Moride, Yola ^j,s   Fabre, Alban ^k   Thibaut, Florence ^l,q   Abenhaim, Lucien ^m,t   Abdollahi, K ^u   Adnet Markovitch, V ^u   Affane, A ^u   Ait Menguellet, A ^u   Ait Belkacem, N ^u   Alexandre, J Y ^u   Amar, G ^u   Ambrozie, C ^u   Anceau, C ^u   Andrade, A ^u   Andrianomanana, T ^u   Antoni, F ^u   Antoniol, B ^u   Archambault, G ^u   Ardiet, G ^u   Artigues, T ^u   Aziz, F ^u   Azoulay, C ^u   Azzazene, R ^u   Baarir, Z ^u   Balais, T ^u   Baloutch, N ^u   bantmann, P ^u   Bareil Guerin, M ^u   Barrere, J ^u   Bart, N ^u   Battistella, N ^u   Beaufils, B ^u   Behm, J ^u   Ben Haouaia, S ^u   Benadhira, R ^u   Benichou, J ^u   Benrhamani, K ^u   Berlag, L ^u   Bernard, H ^u   Bertrand, C ^u   Beyadh, M ^u   Bigot Plantade, L ^u   Bille, A ^u   Biloa Tang, M ^u   Bondon, P ^u   Borrelly, N ^u   Boscq, C ^u   Bottin, E ^u   Bouchefra, A ^u   Boulanger, M ^u   Boulanger, C ^u   Boumerfeg, K ^u   Bouquet, F ^u   Boutaleb, L ^u   Boutten, B ^u   Bouvy, M H ^u   Bouzel, M ^u   Boxus, A ^u   Brehat, A ^u   Briant, P ^u   Brigout, S ^u   Philippe, B ^u   Bruis, C ^u   Cahiez, A ^u   Carbonnel, P ^u   Cariclet, N ^u   Caroli, F ^u   Caron, B ^u   Cassan, I ^u   Castro, B ^u   Caudrillier, A ^u   Chabannes, J M ^u   Chapireau, F ^u   Charrel, C ^u   Chassain, X ^u   Cheliout, W ^u   Chereau, I ^u   Chhor, N ^u   Chiwalo, J ^u   Cleenewerck, F ^u   Clery Melin, P ^u   Collin, H ^u   Conti, J ^u   Cornillon, D ^u   Costard, C ^u   Costi, F ^u   Courcelles, J P ^u   Criquillon Doublet, S ^u   Cros, M ^u   Dammak, A ^u   D'Anjou, A ^u   Danon Cohen, N ^u   Dao Castellana, M H ^u   Dartois, L ^u   Daviet, F ^u   De Beaurepaire, R ^u   De Lamiere, G ^u   De Verbigier, ^u   De Saint Paul H, ^u   Debaene, V ^u   Debaisieux, T ^u   Debien, C ^u   Deblas, C ^u   Debrock, M ^u   Dekar, K ^u   Dekhli, L ^u   Delabie Lafont, J ^u   Delage, A ^u   Delcroix, D ^u   Delmon, C ^u   Delmotte, I ^u   Deluermoz, S ^u   Denes, V ^u   Denizot, H ^u   Desormeaux, A ^u   Dima, D ^u   Drevon, O ^u   Droulot, T ^u   Drucker, H ^u   Dublanchet, O ^u   Dubroca, J M ^u   Dubuc, M ^u   Dumas, C ^u   Dumont, A C ^u   Dupont, J ^u   Dupuy, C ^u   Dutertre, T ^u   Dzieraynski, N ^u   Eldin De Pacoulas, F ^u   Elek, T ^u   Espaze, R ^u   Etchepare, J J ^u   Ezzedine, M ^u   Fabre, I ^u   Fakih, J ^u   Farkas, A ^u   Farrai, A ^u   Faurie, V ^u   Fay, J ^u   Fayed, A ^u   Feraud, A ^u   Feray, D ^u   Ferre, M ^u   Fouldrin, G ^u   Foulet, M ^u   Fradin, J L ^u   Frederic, D ^u   Frey, F ^u   Galy, R ^u   Garnier, B ^u   Gaubert, R ^u   Gauffeny, N ^u   Gauthier, P ^u   Gavaudin, G ^u   Geoffroy, D ^u   Geraud, C ^u   Germain, C ^u   Gervais, E ^u   Gisselmann Patris, M F ^u   Godet, P F ^u   Goetz, H ^u   Goetz, J ^u   Gogue, J ^u   Grau Espel, F ^u   Griguer, J L ^u   Grodet, C ^u   Kirst Grosse, E M ^u   Grosse, E ^u   Guibert Maury, C ^u   Gusse, M ^u   haro pastol, I ^u   Henriet, K ^u   Herdenberger, C ^u   Heurtel, J C ^u   Housson, C ^u   Idrissi, F ^u   Jacob, A ^u   Jacquis, L ^u   Janaud, N ^u   Januel, D ^u   Jeannot, M ^u   Jolly, C ^u   Jost, F ^u   Juglard, G ^u   Kahn, J P ^u   Karar, A ^u   Kerbi, Y ^u   Khettal, M ^u   Khouailid, E M ^u   Klinger, J M ^u   Kourouma, B ^u   Labre, C ^u   Lagodka, A ^u   Lajugie, C ^u   Lambert, O ^u   Lancon, C ^u   Lang, F ^u   Lariviere, J M ^u   Laugier, M ^u   Lauquin, P ^u   Lavoisy, B ^u   Le Borgne, M H ^u   Le Flahec, H ^u   Le Foll, J A ^u   Le Toux, M T ^u   Le Vaou, P ^u   Leborgne, S ^u   Lebrun, A ^u   Lecuyer, M ^u   Lefebvre, I ^u   Lefebvre, N ^u   Legrand, N ^u   Legros, F ^u   Leguay, D ^u   Leignel, C ^u   Lemarie, Y ^u   Lemoine, S ^u   Lemoine, X ^u   Leroy, V ^u   Lesieur, P ^u   Levacon, G ^u   levy, O ^u   Leydier, A ^u   Liard, S ^u   Liling, C ^u   Limousin, S ^u   Llorca, P M ^u   Lorius, J ^u   Lucas Navaro, S ^u   Maggia, M ^u   Magon, J P ^u   Malet Pinsolle, D ^u   Mansour, A ^u   Marcel, J L ^u   Martel, A ^u   Matha, C ^u   May, J P ^u   Mayeur, S ^u   Meary, A ^u   Mekaoui, L ^u   Metton, J P ^u   Metzger, J Y ^u   Meyer, P ^u   Mimran, J ^u   Morault, P ^u   Morcellet, P ^u   Mouric, I ^u   Mortelier, A ^u   Mouchabac, S ^u   Mutet, J M ^u   Nadjar, F ^u   Nardot, F ^u   Navarre Coulaud, A ^u   Nguyen, M ^u   Oliveira, A ^u   Ollier, B ^u   Oury Delamotte, M ^u   Paquis, J ^u   Paradas, C ^u   Partouche, N ^u   Paul, S ^u   Pelissie Du Rausas, R ^u   Peretti, C S ^u   Peron, S ^u   Petit, M R ^u   Peutillot, J F ^u   Pichard, V ^u   Pillette, D ^u   Piquet, T ^u   Platteau, S ^u   Pontacq, J L ^u   Portenart, C ^u   Preterre, P ^u   Princet, P ^u   Pujet Becq, A M ^u   Pupeschi, G ^u   Quintard, M ^u   rabreau, D ^u   Rahiqui, H ^u   Rangondi, F ^u   Rascle, C ^u   Raucoules, D ^u   Raymondet, P ^u   Regel, I ^u   Regina, W ^u   Renard, M ^u   Rimlinger, L ^u   Robin, M ^u   Roeser, C ^u   Rosetti, R ^u   Rossi, C ^u   Rouillon, F ^u   Roussel, P ^u   Roy, M ^u   Rozieres, J L ^u   Rust, A ^u   Saba, G ^u   Saint Andre, C ^u   Saint Bauzel, J F ^u   Saladini, O ^u   Sallustrau, J F ^u   Sangare, M L ^u   Secret Bobolakis, I ^u   Sedivy, F ^u   Sehran, A ^u   Seigneurie, A S ^u   Sichaib, H ^u   Skulszka, A ^u   Stamatiadis, L ^u   Staurenghi, J L ^u   Sztern, A ^u   Taieb, L ^u   Taleb, M ^u   Talichet, L ^u   Tarissan, J M ^u   Thevenon, C ^u   Thibaut, F ^u   Thiebault Stefanik, M P ^u   Thomas Simon, C ^u   Tombelaine, A ^u   Torres, D ^u   Tourrel, C ^u   Touzart, D ^u   Trichard, C ^u   Triebsch, F ^u   Urucu Milcent, D ^u   Van Nedervelde, C ^u   Vaneecloo, P ^u   Verdoux, H ^u   Verlhac, A ^u   Viala, A ^u   Vidal, H ^u   Vileyn, F ^u   Villeneuve, C ^u   Walter, C ^u   Weibel, H ^u   Weil, S ^u   Wertz, E ^u   Wizla, F ^u   Zahzouh, S ^u   Zangerlin, H ^u   more..

^a University Versailles Saint Quentin UVSQ   (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

^c Universite Paris Sud   (France)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^e INSERM U657   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g Paris Descartes University   (France)

^h UNIV LILLE   (France)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k LA SER   (France)

^l HÔPITAL CHARLES NICOLLE   (France)

^m LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁿ MCGILL UNIVERSITY   (Canada)

^o ROUEN UNIVERSITY HOSPITAL   (France)

^p ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^q INSERM   (France)

^r LILLE UNIVERSITY HOSPITAL   (France)

^s CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^t London School of Hygiene Tropical Medicine   (United Kingdom)

^u Faculté de Médecine et de Pharmacie ^*

more..

Author keywords

Antipsychotics; Cohort study; Hospitalisation; Long acting injectable antipsychotics; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; CYAMEMAZINE; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; LONG ACTING DRUG; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; PIPOTIAZINE PALMITATE; RISPERIDONE; SULPIRIDE; TIAPRIDE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRANCE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA;

EID: 84856267843     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.10.022     Document Type: Article

References (27)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-IV-TR 2000, Washington, DC. 4th Text-Revised Ed.
2. Bai Y.M., Ting Chen T., Chen J.Y., Chang W.H., Wu B., Hung C.H., Kuo Lin W. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry 2007, 68(8):1218-1225.
3. Chue P., Eerdekens M., Augustyns I., Lachaux B., Molcan P., Eriksson L., Pretorius H., David A.S. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 2005, 15(1):111-117.
4. De la Gándara J., San Molina L., Rubio G., Rodriguez-Morales A., Hidalgo Borrajo R., Burón J.A. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. Expert Rev. Neurother. 2009, 9(10):1463-1474.
5. Di Lorenzo R., Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr. Dis. Treat. 2010, 6:573-581.
6. Doering S., Müller E., Köpcke W., Pietzcker A., Gaebel W., Linden M., Müller P., Müller-Spahn F., Tegeler J., Schüssler G. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr. Bull. 1998, 24(1):87-98.
7. Eichler H.G., Bloechl-Daum B., Abadie E., Barnett D., König F., Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat. Rev. Drug Discov. 2010, 9(4):277-291.
8. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33(6):766-771.
9. Gilbody S.M., Bagnall A.M., Duggan L., Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. 2000, 3. CD002306.
10. Glynn R.J., Schneeweiss S., Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin. Pharmacol. Toxicol. 2006, 98(3):253-259.
11. Guy W. Clinical global impression. ECDEU Assessment Manual for Psychopharmacology, revised 1976, 217-222. National Institute of Mental Health, Rockville. W. Guy (Ed.).
12. Hodgson R., Bushe C., Hunter R. Measurement of long-term outcomes in observational and randomised controlled trials. Br. J. Psychiatry Suppl. 2007, 50:s78-s84.
13. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003, 160(6):1125-1132.
14. Keks N.A., Ingham M., Khan A., Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br. J. Psychiatry 2007, 191:131-139.
15. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. linical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
16. Macfadden W., Ma Y.W., Thomas Haskins J., Bossie C.A., Alphs L. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgemont) 2010, 7(11):23-31.
17. Montout C., Casadebaig F., Lagnaoui R., Verdoux H., Philippe A., Begaud B., Moore N. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr. Res. 2002, 57(2-3):147-156.
18. Nasrallah H.A. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr. Scand. 2007, 115(4):260-267.
19. Novick D., Haro J.M., Suarez D., Vieta E., Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr. Res. 2009, 108(1-3):223-230.
20. Olivares J.M., Peuskens J., Pecenak J., Resseler S., Jacobs A., Akhras K.S. e-STAR Study Group, 2009. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr. Med. Res. Opin. 2009, 25(9):2197-2206.
21. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
22. Rainer M.K. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr. Dis. Treat. 2008, 4(5):919-927.
23. Rosenheck R.A., Krystal J.H., Lew R., Barnett P.G., Fiore L., Valley D., Thwin S.S., Vertrees J.E., Liang M.H. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N. Engl. J. Med. 2011, 364(9):842-851. CSP555 Research Group.
24. Rouillon F., Gittelman M. The French Mental Health System. Int. J. Ment. Health 2009, 38(4):3-24.
25. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33. quiz 34-57.
26. Sox H.C., Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann. Intern. Med. 2009, 151(3):203-205.
27. Willis M., Svensson M., Löthgren M., Eriksson B., Berntsson A., Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur. J. Health Econ. 2010, 11(6):585-594.